As BioNTech progresses with its goal to grow into a “fully integrated immunotherapy powerhouse,” the German biotech is e | ...

When the smoke cleared, BioNTech's shares closed the day more than 6% lower. The Food and Drug Administration (FDA), a ...

BNT327, a PD-L1/VEGF therapy, is still currently being manufactured in China, but BioNTech is working to establish a ...

In late April, Summit Therapeutics revealed interim OS data from HARMONi-2 for its PD-1/VEGF bispecific antibody, ivonescimab ...

German COVID-19 vaccine maker BioNTech said on Monday that Ramon Zapata-Gomez will become its new finance chief from July 1.

By Akin Nazli in Belgrade Ugur Sahin, owner of BioNTech (Nasdaq/BNTX), has been ranked second in Forbes Turkey’s Top 100 ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

Despite a net loss, BioNTech SE (BNTX) remains focused on oncology advancements and maintains a strong financial position ...

Dr. Peter Marks, a Food and Drug Administration official who had a leading role in vaccine regulation, was ousted by Health and Human Services Secretary Robert F. Kennedy Jr., and alleged Kennedy was ...

BioNTech recently appointed Ramón Zapata-Gomez as its new CFO, a move reflecting the company's focus on realigning its financial strategy, particularly in oncology. Despite confirming its ...

German biotech BioNTech (Nasdaq: BNTX) saw its shares dip 3.4% to $101.44 today, after it reported financial results for the ...

BioNTech (NasdaqGS:BNTX) recently appointed Ramón Zapata-Gomez as its new CFO, a move reflecting the company's focus on realigning its financial strategy, particularly in oncology. Despite confirming ...